Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth

被引:6
作者
Artham, Sandeep [1 ]
Juras, Patrick K. [1 ]
Goyal, Aditi [1 ]
Chakraborty, Prabuddha [2 ]
Byemerwa, Jovita [1 ]
Liu, Siyao [3 ]
Wardell, Suzanne E. [1 ]
Chakraborty, Binita [1 ]
Crowder, Daniel [1 ]
Lim, Felicia [1 ]
Strawser, Corinne H. [1 ]
Newlin, Madeline [1 ]
Racioppi, Alessandro [1 ]
Dent, Susan [4 ]
Mirminachi, Babak [5 ]
Roper, Jatin [1 ,5 ]
Perou, Charles M. [3 ]
Chang, Ching-Yi [1 ]
McDonnell, Donald P. [1 ]
机构
[1] Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA
[2] Univ N Carolina, Dept Genet, Chapel Hill, NC USA
[3] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[4] Duke Univ, Sch Med, Dept Med, Div Med Oncol, Durham, NC USA
[5] Duke Univ, Sch Med, Dept Med, Div Gastroenterol, Durham, NC USA
来源
SCIENCE ADVANCES | 2024年 / 10卷 / 39期
关键词
COLORECTAL-CANCER; ENDOCRINE THERAPY; RECEPTOR; MICE; PEMBROLIZUMAB; INFILTRATION; ACTIVATION; EXPRESSION; SURVIVAL; HEALTH;
D O I
10.1126/sciadv.adp2442
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Estrogens regulate eosinophilia in asthma and other inflammatory diseases. Further, peripheral eosinophilia and tumor-associated tissue eosinophilia (TATE) predicts a better response to immune checkpoint blockade (ICB) in breast cancer. However, how and if estrogens affect eosinophil biology in tumors and how this influences ICB efficacy has not been determined. Here, we report that estrogens decrease the number of peripheral eosinophils and TATE, and this contributes to increased tumor growth in validated murine models of breast cancer and melanoma. Moreover, estrogen signaling in healthy female mice also suppressed peripheral eosinophil prevalence by decreasing the proliferation and survival of maturing eosinophils. Inhibiting estrogen receptor (ER) signaling decreased tumor growth in an eosinophil-dependent manner. Further, the efficacy of ICBs was increased when administered in combination with anti-estrogens. These findings highlight the importance of ER signaling as a regulator of eosinophil biology and TATE and highlight the potential near-term clinical application of ER modulators to increase ICB efficacy in multiple tumor types.
引用
收藏
页数:18
相关论文
共 63 条
  • [1] Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study
    Ali, H. Raza
    Chlon, Leon
    Pharoah, Paul D. P.
    Markowetz, Florian
    Caldas, Carlos
    [J]. PLOS MEDICINE, 2016, 13 (12)
  • [2] Peripheral blood eosinophilia may be a prognostic biomarker in non-small cell lung cancer patients treated with immunotherapy
    Alves, Adelaide
    Dias, Margarida
    Campainha, Sergio
    Barroso, Ana
    [J]. JOURNAL OF THORACIC DISEASE, 2021, 13 (05) : 2716 - 2727
  • [3] The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor
    Andreano, Kaitlyn J.
    Baker, Jennifer G.
    Park, Sunghee
    Safi, Rachid
    Artham, Sandeep
    Oesterreich, Steffi
    Jeselsohn, Rinath
    Brown, Myles
    Sammons, Sarah
    Wardell, Suzanne E.
    Chang, Ching-yi
    Norris, John D.
    McDonnell, Donald P.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2020, 19 (07) : 1395 - 1405
  • [4] Eosinophilia in cancer and its regulation by sex hormones
    Artham, Sandeep
    Chang, Ching-Yi
    McDonnell, Donald P.
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2023, 34 (01) : 5 - 20
  • [5] EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER plus advanced breast cancer
    Bardia, Aditya
    Aftimos, Philippe
    Bihani, Teeru
    Anderson-Villaluz, Alfred T.
    Jung, JungAh
    Conlan, Maureen G.
    Kaklamani, Virginia G.
    [J]. FUTURE ONCOLOGY, 2019, 15 (28) : 3209 - 3218
  • [6] IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer
    Blomberg, Olga S.
    Spagnuolo, Lorenzo
    Garner, Hannah
    Voorwerk, Leonie
    Isaeva, Olga I.
    van Dyk, Ewald
    Bakker, Noor
    Chalabi, Myriam
    Klaver, Chris
    Duijst, Maxime
    Kersten, Kelly
    Bruggemann, Marieke
    Pastoors, Dorien
    Hau, Cheei-Sing
    Vrijland, Kim
    Raeven, Elisabeth A. M.
    Kaldenbach, Daphne
    Kos, Kevin
    Afonina, Inna S.
    Kaptein, Paulien
    Hoes, Louisa
    Theelen, Willemijn S. M. E.
    Baas, Paul
    Voest, Emile E.
    Beyaert, Rudi
    Thommen, Daniela S.
    Wessels, Lodewyk F. A.
    de Visser, Karin E.
    Kok, Marleen
    [J]. CANCER CELL, 2023, 41 (01) : 106 - +
  • [7] Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells
    Bourdeau, Veronique
    Deschenes, Julie
    Laperriere, David
    Aid, Malika
    White, John H.
    Mader, Sylvie
    [J]. NUCLEIC ACIDS RESEARCH, 2008, 36 (01) : 76 - 93
  • [8] ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
    Brett, Jamie O.
    Spring, Laura M.
    Bardia, Aditya
    Wander, Seth A.
    [J]. BREAST CANCER RESEARCH, 2021, 23 (01)
  • [9] Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells
    Carretero, Rafael
    Sektioglu, Ibrahim M.
    Garbi, Natalio
    Salgado, Oscar C.
    Beckhove, Philipp
    Haemmerling, Guenter J.
    [J]. NATURE IMMUNOLOGY, 2015, 16 (06) : 609 - +
  • [10] Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma
    Chakraborty, Binita
    Byemerwa, Jovita
    Shepherd, Jonathan
    Haines, Corinne N.
    Baldi, Robert
    Gong, Weida
    Liu, Wen
    Mukherjee, Debarati
    Artham, Sandeep
    Lim, Felicia
    Bae, Yeeun
    Brueckner, Olivia
    Tavares, Kendall
    Wardell, Suzanne E.
    Hanks, Brent A.
    Perou, Charles M.
    Chang, Ching-Yi
    McDonnell, Donald P.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (23)